Pharma and Pharmaceutical - Pharma Rep Focus

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

MedCity News

NOVEMBER 6, 2024

Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The post Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M appeared first on MedCity News.

FDA

FDA Pharma Pharmaceutical Biopharma

Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

MedCity News

FEBRUARY 7, 2025

Bain Capitals buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group.

Pharma

Pharma Pharmaceutical Biopharma

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway

MedCity News

APRIL 7, 2025

Rhythm Pharmaceuticals drug Imcivree met the body mass index reduction goals of a Phase 3 test in hypothalamic obesity, an acquired form of obesity stemming from dysregulation of the MC4R pathway in the hypothalamus. The engineered peptide drug is already approved for two genetically driven types of obesity.

Pharma

Pharma Engineering Pharmaceutical FDA

Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels

MedCity News

MARCH 23, 2025

But Apellis Pharmaceuticals Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. The post Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels appeared first on MedCity News.

FDA

FDA Pharma Pharmaceutical Biopharma

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

MedCity News

NOVEMBER 25, 2024

BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.

Competition

Competition FDA Pharma Pharmaceutical

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

MedCity News

JANUARY 31, 2025

Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The post Vertex Pharmas Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds appeared first on MedCity News.

FDA

FDA Medicine Pharma Pharmaceutical

Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval

MedCity News

NOVEMBER 18, 2024

The post Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval appeared first on MedCity News. Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin.

Pharmaceutical

Pharmaceutical FDA Biopharma Pharma

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s

MedCity News

MARCH 28, 2025

Novo Nordisk gets global rights to Lexicon Pharmaceuticals LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The post Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s appeared first on MedCity News.

Pharma

Pharma Pharmaceutical Biopharma

Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult

MedCity News

FEBRUARY 19, 2025

Accepted applicants will be admitted to Altitude Lab, the Salt Lake City biotech accelerator formed by Recursion Pharmaceuticals. The post Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult appeared first on MedCity News.

Pharma

Pharma Pharmaceutical Biopharma

Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition

MedCity News

OCTOBER 14, 2024

Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Longboard Pharma Acquisition appeared first on MedCity News. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome.

Pharma

Pharma Pharmaceutical Biopharma

FDA Approval of Alopecia Drug Positions Sun Pharma to Compete With Eli Lilly, Pfizer

MedCity News

JULY 28, 2024

Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. The post FDA Approval of Alopecia Drug Positions Sun Pharma to Compete With Eli Lilly, Pfizer appeared first on MedCity News. Leqselvi is now FDA approved for treating severe alopecia areata.

FDA

FDA Pharma Pharmaceutical Biopharma

Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients

MedCity News

JULY 18, 2024

Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). Phathom licensed its flagship product from Takeda Pharmaceutical. The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News.

Pharma

Pharma Patients FDA Pharmaceutical

Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis

MedCity News

SEPTEMBER 24, 2024

Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas. The post Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis appeared first on MedCity News.

Pharma

Pharma Pharmaceutical Medical Biopharma

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

MedCity News

AUGUST 12, 2024

FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.

FDA

FDA Pharma Competition Pharmaceutical

How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come

MedCity News

OCTOBER 20, 2024

Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News.

Pharma

Pharma Leads Pharmaceutical Biopharma

Vertex Pharma Bolsters Immunology Profile With $4.9B Alpine Immune Sciences Acquisition

MedCity News

APRIL 10, 2024

Vertex Pharmaceuticals gains a Phase 3-ready Alpine Immune Sciences drug with potential applications in a wide range of immunological disorders. The post Vertex Pharma Bolsters Immunology Profile With $4.9B The lead indication for the Alpine drug, povetacicept, is the chronic kidney disease IgA nephropathy.

Pharma

Pharma Pharmaceutical Leads Biopharma

A Wearable Tech Gives Pharmas & Therapists Better Feel for Changes in Mental Health

MedCity News

APRIL 14, 2024

Pharmaceutical companies use Feel Therapeutics’ technology to monitor the mental state of participants in clinical trials of behavioral medications. The post A Wearable Tech Gives Pharmas & Therapists Better Feel for Changes in Mental Health appeared first on MedCity News.

Pharma

Pharma Medical Pharmaceutical Biopharma

The 2025 Pharma Toolkit for Virtual Medical Education

Impetus Digital

DECEMBER 23, 2024

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders.

Education

Education Medical Pharma Training

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

MedCity News

SEPTEMBER 9, 2024

The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News.

Leads

Leads Pharma Pharmaceutical Medical

Pfizer’s Migraine Drug Approval Triggers $475M Payment to Royalty Pharma

MedCity News

MARCH 16, 2023

Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy’s previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.

Pharma

Pharma Pharmaceutical Biopharma

Why I Went From Abbot Pharma Sales to 1099 With Bruce Brown

Evolve Your Success

FEBRUARY 5, 2025

From navigating the halls of Abbott Laboratories and Knoll Pharmaceutical Company to pioneering his path as an independent medical device sales rep, Bruce Brown’s career journey challenges traditional sales wisdom.

Sales

Sales Medical sales Pharma Medical

Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal

MedCity News

MARCH 31, 2025

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertexs entry into type 1 diabetes.

Pharmaceutical

Pharmaceutical Medical Biopharma Pharma

Top 5 Strategic Focus Areas for Global Pharma Marketers in 2024

MedCity News

FEBRUARY 14, 2024

2024 presents an exciting yet challenging landscape for global pharma marketers.

Marketing

Marketing Pharma Pharmaceutical Patients

The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender

MedCity News

DECEMBER 26, 2024

Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.

Pharmaceutical

Pharmaceutical Biopharma Pharma

Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD

MedCity News

MARCH 25, 2025

Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration.

Pharma

Pharma FDA Pharmaceutical Biopharma

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy.

Pharmaceutical

AI-Powered Insights for Personalized Customer Experiences: The Art of Data-Driven Engagement

MedCity News

NOVEMBER 26, 2024

While advanced analytics and AI can unlock unprecedented insights, it’s the thoughtful application of these insights that transforms routine interactions between pharmaceutical representatives and healthcare providers into lasting relationships.

Healthcare Provider

Healthcare Provider Pharmaceutical Healthcare Healthcare

Unlocking growth: How GenAI can help pharma companies convert new clients

PharmaVoice

APRIL 8, 2024

GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 million by 2032.

Pharma

Pharma Pharmaceutical Marketing

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

Fierce Pharma

OCTOBER 31, 2024

Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potentia | Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra.

Sales

Sales Pharmaceutical Marketing

The Financial Potential of Convertible Notes in the Pharmaceutical Sector

MedCity News

JUNE 26, 2024

The post The Financial Potential of Convertible Notes in the Pharmaceutical Sector appeared first on MedCity News. These notes serve not only as a means to raise capital but also as a bridge to future financing rounds or significant liquidity events.

Pharmaceutical

Pharmaceutical Biopharma Pharma

A First for Fatty Liver: FDA Approves Madrigal Pharma NASH Drug

MedCity News

MARCH 14, 2024

The FDA has approved Madrigal Pharmaceuticals drug Rezdiffra as a treatment for the fatty liver disease NASH (also called MASH). It’s the first treatment for the chronic condition, which has been growing in prevalence.

FDA

FDA Pharma Pharmaceutical Biopharma

The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights

MedCity News

OCTOBER 15, 2024

PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies. The post The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights appeared first on MedCity News.

Healthcare

Healthcare Healthcare Pharma Pharmaceutical

Finding a Collaborative, Data-Driven Future for Pharma

MedCity News

OCTOBER 24, 2023

The future of pharmaceutical innovation hinges on enhanced data discovery and collaboration. Through data sharing and collective effort, the pharmaceutical industry can accelerate the development of new therapies.

Pharma

Pharma Pharmaceutical Biopharma

Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug

MedCity News

DECEMBER 17, 2024

The Teva Pharmaceuticals and Sanofi drug, duvakitug, showed statistically significant and clinically meaningful results in a Phase 2b study in ulcerative colitis and Crohns disease. The drug is part of an emerging class of therapies that target TL1A, a protein involved in signaling that drives inflammation.

Pharmaceutical

Pharmaceutical Biopharma Pharma

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

MedCity News

DECEMBER 30, 2024

Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimers agitation drug. One Phase 3 test of Auvelity met its main goal in Alzheimers agitation while the drugs other pivotal trial showed numerical improvement that fell short of statistical significance.

FDA

FDA Pharmaceutical products Pharmaceutical Biopharma

How pharma companies can leverage asynchronous telemedicine

MedCity News

OCTOBER 25, 2022

Through apps, pharmaceutical companies can actually influence patient adherence and mindset after that patient has been prescribed that company’s medication by their physician.

Physicians

Physicians Pharma Medical Patients

After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout

MedCity News

SEPTEMBER 26, 2023

Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.

Pharma

Pharma Pharmaceutical FDA Biopharma

Building Resilience: CDMO Strategies for Drug Supply Chain Stability

MedCity News

FEBRUARY 2, 2025

As the pharmaceutical landscape evolves, small-molecule CDMOs will be essential in balancing supply and demand, driving innovation, and improving patient outcomes. They must continue embracing innovation and strategic agility to survive and thrive in this complex environment.

Pharmaceutical

Pharmaceutical Patients Biopharma Pharma

Longboard Pharma Trial Data Show How It Could Stand Out in the Epilepsy Field

MedCity News

JANUARY 2, 2024

Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.

Safety

Safety Pharma Pharmaceutical Biopharma

Fat-shedding pill’s data lead to a $132M funding round for startup Rivus Pharma

MedCity News

SEPTEMBER 23, 2022

Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure.

Leads

Leads Pharma Pharmaceutical Biopharma

Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug

MedCity News

APRIL 17, 2025

The pharmaceutical giant plans global regulatory submissions starting at the end of this year. The first Phase 3 results for Eli Lillys daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes.

Medicine

Medicine Leads Pharmaceutical Patients

AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda

MedCity News

MARCH 14, 2024

AstraZeneca is acquiring Amolyt Pharma to get eneboparatide, a drug in Phase 3 development for treating hypoparathyroidism. Takeda Pharmaceutical markets the only FDA-approved treatment for this rare disease, but the Japanese pharmaceutical giant plans to stop making the drug.

Pharma

Pharma FDA Pharmaceutical Marketing

FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine

MedCity News

SEPTEMBER 20, 2023

ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.

FDA

FDA Pharma Pharmaceutical Biopharma

EyePoint Pharma Sells U.S. Rights to Eye Med to Become Pure Play Drug Developer

MedCity News

MAY 18, 2023

rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline. By selling U.S. The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy.

Pharma

Pharma Pharmaceutical Leads Biopharma

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

Trending Sources

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway

Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s

Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult

Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition

FDA Approval of Alopecia Drug Positions Sun Pharma to Compete With Eli Lilly, Pfizer

Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients

Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come

Vertex Pharma Bolsters Immunology Profile With $4.9B Alpine Immune Sciences Acquisition

A Wearable Tech Gives Pharmas & Therapists Better Feel for Changes in Mental Health

The 2025 Pharma Toolkit for Virtual Medical Education

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

Pfizer’s Migraine Drug Approval Triggers $475M Payment to Royalty Pharma

Why I Went From Abbot Pharma Sales to 1099 With Bruce Brown

Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal

Top 5 Strategic Focus Areas for Global Pharma Marketers in 2024

The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender

Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

AI-Powered Insights for Personalized Customer Experiences: The Art of Data-Driven Engagement

Unlocking growth: How GenAI can help pharma companies convert new clients

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

The Financial Potential of Convertible Notes in the Pharmaceutical Sector

A First for Fatty Liver: FDA Approves Madrigal Pharma NASH Drug

The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights

Finding a Collaborative, Data-Driven Future for Pharma

Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

How pharma companies can leverage asynchronous telemedicine

After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout

Building Resilience: CDMO Strategies for Drug Supply Chain Stability

Longboard Pharma Trial Data Show How It Could Stand Out in the Epilepsy Field

Fat-shedding pill’s data lead to a $132M funding round for startup Rivus Pharma

Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug

AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda

FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine

EyePoint Pharma Sells U.S. Rights to Eye Med to Become Pure Play Drug Developer

Stay Connected